This is a preprint.
Central role of glycosylation processes in human genetic susceptibility to SARS-CoV-2 infections with Omicron variants
- PMID: 39606378
- PMCID: PMC11601703
- DOI: 10.1101/2024.11.21.24317689
Central role of glycosylation processes in human genetic susceptibility to SARS-CoV-2 infections with Omicron variants
Update in
-
Central role of glycosylation processes in human genetic susceptibility to SARS-CoV-2 infections with Omicron variants.Nat Genet. 2026 Feb;58(2):299-306. doi: 10.1038/s41588-025-02484-9. Epub 2026 Jan 22. Nat Genet. 2026. PMID: 41571831 Free PMC article.
Conflict of interest statement
S.Brunak has ownerships in Intomics A/S, Hoba Therapeutics Aps, Novo Nordisk A/S, Lundbeck A/S, ALK abello A/S, Eli Lilly and Co and managing board memberships in Proscion A/S and Intomics A/S. C.E. has received unrestricted research grants from Novo Nordisk administered by Aarhus University and Abbott Diagnostics administered by Aarhus University Hospital. C.E. received no personal fees. K.G. received a Janssen Pharma research grant and is on the advisory board of Otsuka Pharma. L.B. currently works for MSD Denmark. All other authors report no competing interests.
Figures
References
-
- COVID-19 cases | WHO COVID-19 dashboard. https://data.who.int/dashboards/covid19/cases (accession date: 14 November 2024).
-
- Markov P. V. et al. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 2023 216 21, 361–379 (2023). - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous